Eculizumab, sold under the brand name Soliris among others, is a recombinant humanized monoclonal antibody used to treat paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica.

Eculizumab is a long-acting humanized monoclonal antibody targeted against complement C5. It inhibits the cleavage of C5 into C5a and C5b and hence inhibits deployment of the terminal complement system including the formation of MAC. In PNH patients, eculizumab profoundly inhibits haemolysis.

2007年5月16日 · Mechanism of action. Eculizumab is a monoclonal antibody that targets complement protein C5, preventing cleavage to C5a and C5b, and the formation of the terminal complement complex C5b-9. 7,1,2 Inhibition of this complex prevents complement mediated intravascular hemolysis in paroxysmal nocturnal hemoglobunuria, complement mediated ...

In this review, we provide insight into the PK and pharmacodynamics (PD) of eculizumab, for both reported on- and off-label use. Furthermore, PK targets within different diseases are discussed to optimize dosing.

2020年2月9日 · Mechanism of Action. Eculizumab is a humanized monoclonal IgG antibody that binds to complement protein C5, preventing cleavage into C5a and C5b. Blocking the formation of C5b inhibits the subsequent formation of terminal complex C5b-9 or MAC.

2017年2月23日 · Eculizumab is a first-in-class, breakthrough drug for PNH that prevents thrombosis (the leading cause of death in PNH), improves quality of life, and often eliminates the need for blood transfusions; however, most patients continue to have low level hemolysis and mild to moderate anemia.

2024年12月12日 · Eculizumab's mechanism of action involves binding to a specific protein called complement protein C5 in the blood, preventing it from breaking apart into other proteins that can destroy red blood cells.

Soliris™ (eculizumab), Concentrated solution for intravenous infusion Initial U.S. Approval: 2007 WARNING: SERIOUS MENINGOCOCCAL INFECTIONS See full prescribing information for complete boxed...

2024年9月1日 · Eculizumab’s mechanism of action focuses on targeting the complement system. It does so by binding to complement protein C5, effectively inhibiting its cleavage into C5a and C5b. This, in turn, prevents the formation of the membrane attack complex (MAC), which is responsible for cell lysis and inflammation.

2024年10月9日 · Mechanism Of Action. Eculizumab, the active ingredient in SOLIRIS, is a monoclonal antibody that specifically binds to the complement protein C5 with high affinity, thereby inhibiting its cleavage to C5a and C5b and preventing the generation of the terminal complement complex C5b-9.